Mast cells in collagen diseases

Naoya Mikita, Yutaka Inaba, Takashi Yoshimasu, Nobuo Kanazawa, Fukumi Furukawa

Article ID: 96
Vol 3, Issue 2, 2019

VIEWS - 1084 (Abstract)

Abstract


Mast cells are involved in many immune reactions and diseases through 1) the expressions of several receptors, 2) productions of various mediators such as histamine, cytokines, and chemokines, 3) direct interactions with immune cells. Besides allergic diseases, mast cells have been also assumed to be involved in autoimmune diseases such as bullous pemphigoid, rheumatoid arthritis, and multiple sclerosis. Moreover, several studies reported the involvement of mast cells in collagen disease. In this article, we review recent findings about the role of mast cells especially in systemic lupus erythematosus and systemic sclerosis. In these diseases, mast cells seem to be involved in local inflammation and tissue damage partially in the targeted organ rather than the development of autoimmunity including production of autoantibodies.

Keywords


mast cells; systemic lupus erythematosus; systemic sclerosis

Full Text:

PDF


References


1. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle.

2. Nat Rev Immunol. 2014; 14(7): 478-494. doi: 10.1038/nri3690.

3. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10(6): 440-452. doi: 10.1038/nri2782.

4. Varricchi G, Galdiero MR, Loffredo S, et al. Are Mast cells MASTers in cancer? Front Immunol. 2017; 8: 424. doi: 10.3389/fimmu.2017.00424. eCollection 2017.

5. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature. 2002; 420(6917): 875-878. doi: 10.1038/nature01324

6. Sayed BA, Christy A, Quirion MR, et al. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008; 26: 705-39. doi: 10.1146/annurev.immunol.26.021607.090320.

7. Yu X, Kasprick A, Petersen F. Revisiting the role of mast cells in autoimmunity. Autoimmun Rev. 2015; 14(9): 751-9. doi: 10.1016/j.autrev.2015.04.008.

8. Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 2006; 176(4): 2238-48. doi:10.4049/jimmunol.176.4.2238

9. Gri G, Piconese S, Frossi B, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008; 29(5): 771-81. doi: 10.1016/j.immuni.2008.08.018.

10. Rodrigues CP, Ferreira AC, Pinho MP, et al. Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells. Front Immunol. 2016; 7: 9. doi: 10.3389/fimmu.2016.00009.

11. Nigrovic PA, Lee DM. Mast cells in autoantibody responses and arthritis. Novartis Found Symp. 2005; 271: 200-209.

12. Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002; 297(5587): 1689-92. doi:10.1126/science.1073176

13. Corr M, Crain B. The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis. J Immunol. 2002;169(11):6604-9. doi:10.4049/jimmunol.169.11.6604

14. Nigrovic PA, Binstadt BA, Monach PA, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A. 2007; 104(7): 2325-30. doi:10.1073/pnas.0610852103

15. Xu D, Jiang HR, Li Y, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 2010; 184(5): 2620-2626. doi: 10.4049/jimmunol.0902685.

16. Rodewald HR, Feyerabend TB. Widespread immunological functions of mast cells: fact or fiction? Immunity. 2012; 37(1): 13-24. doi:10.1016/j.immuni.2012.07.007.

17. Feyerabend TB, Weiser A, Tietz A, et al. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity. 2011; 35(5): 832-44. doi: 10.1016/j.immuni.2011.09.015.

18. Yokota M, Suzuki K, Tokoyoda K, et al. Roles of mast cells in the pathogenesis of inflammatory myopathy. Arthritis Res Ther. 2014; 16(2): R72. doi: 10.1186/ar4512.

19. Shrestha S, Wershil B, Sarwark JF, et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010; 62(9): 2813-2822. doi: 10.1002/art.27529.

20. Konttinen YT, Hietanen J, Virtanen I, et al. Mast cell derangement in salivary glands in patients with Sjögren's syndrome. Rheumatol Int. 2000;19(4):141-147.

21. Blank U, Essig M, Scandiuzzi L, et al. Mast cells and inflammatory kidney disease. Immunol Rev. 2007; 217: 79-95. doi: 10.1111/j.1600-065X.2007.00503.x

22. Kaczmarczyk K, Kosalka J, Soja J, et al. Renal interstitial mast cell counts differ across classes of proliferative lupus nephritis. Folia Histochem Cytobiol. 2014; 52(3): 218-224. doi: 10.5603/FHC.2014.0025

23. Danilewicz M, Wagrowska-Danilewicz M. Quantitative analysis of interstitial mast cells in lupus and non-lupus membranous glomerulopathy. Pol J Pathol. 2001; 52(4): 211-217.

24. Lin L, Gerth AJ, Peng SL. Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis. Immunol Lett. 2004; 91(2-3): 93-97. doi:10.1016/j.imlet.2003.11.014

25. Madjene LC, Pons M, Danelli L, et al. Mast cells in renal inflammation and fibrosis: lessons learnt from animal studies. Mol Immunol. 2015; 63(1): 86-93. doi: 10.1016/j.molimm.2014.03.002.

26. Ravinal RC, Costa RS, Coimbra TM, et al. Mast cells, TGF-beta1 and myofibroblasts expression in lupus nephritis outcome. Lupus. 2005; 14(10): 814-821. doi: 10.1191/0961203305lu2188oa

27. Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med. 2010; 16(6): 701-707. doi: 10.1038/nm.2159.

28. Uede M, Nakamura Y, Yamamoto Y, et al. No differences in number and distribution of dermal mast cells between acute and chronic cutaneous lupus erythematosus. Autoimmune Dis Ther Approach. 2014; 2: 109. doi: 10.14437/2378-6337-1-109

29. Furukawa F, Tanaka H, Sekita K, et al. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res. 1984; 276(3): 186-194.

30. Tachibana T, Furukawa F, Taniguchi S, et al. Histamine metabolism in skin of MRL/l mice. Arch Dermatol Res. 1985; 278(1): 57-60.

31. Inaba Y, Kanazawa N, Yoshimasu T, et al. Severer lupus erythematosus-like skin lesions in MRL/lpr mice with homozygous Kitwsh/wsh mutation. Mod Rheumatol. 2017; 11: 1-8. doi: 10.1080/14397595.2017.1341591.

32. van Nieuwenhuijze AE, Cauwe B, Klatt D, et al. Lpr-induced systemic autoimmunity is unaffected by mast cell deficiency. Immunol Cell Biol. 2015; 93(10): 841-848. doi: 10.1038/icb.2015.49.

33. Yukawa S, Yamaoka K, Sawamukai N, et al. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol. 2013; 23(6): 1151-1157. doi: 10.1007/s10165-012-0813-8.

34. Hügle T, Hogan V, White KE, et al. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011; 63(3): 795-799. doi: 10.1002/art.30190.

35. Fraticelli P, Gabrielli B, Pomponio G, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014; 16(4): R144. doi: 10.1186/ar4606.

36. Gordon J1, Udeh U, Doobay K, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol. 2014; 32(6 Suppl 86): S189-193.

37. Bagnato G, Roberts WN, Sciortino D, et al. Mastocytosis and systemic sclerosis: a clinical association. Clin Mol Allergy. 2016; 14: 13. doi:10.1186/s12948-016-0050-3

38. Frigui M, Dupin N, Carlotti A, et al. Telangiectasic mastocytosis with systemic sclerosis. Presse Med. 2013; 42(5):902-904. doi: 10.1016/j.lpm.2012.10.014.

39. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999; 112(4): 456-462. DOI:10.1046/j.1523-1747.1999.00528.x

40. Everett ET, Pablos JL, Harley RA, et al. The role of mast cells in the development of skin fibrosis in tight-skin mutant mice. Comp Biochem Physiol A Physiol. 1995; 110(2): 159-165.

41. Shiota N, Kakizoe E, Shimoura K, et al. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br J Pharmacol. 2005; 145(4): 424-431. DOI:10.1038/sj.bjp.0706209

42. Yamamoto T, Takahashi Y, Takagawa S, et al. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol. 1999; 26(12): 2628-2634.

43. Willenborg S, Eckes B, Brinckmann J, et al. Genetic ablation of mast cells redefines the role of mast cells in skin wound healing and bleomycin-induced fibrosis. J Invest Dermatol. 2014; 134(7): 2005-2015. doi: 10.1038/jid.2014.12.

44. Singh J, Shah R, Singh D. Targeting mast cells: Uncovering prolific therapeutic role in myriad diseases. Int Immunopharmacol. 2016; 40: 362-384. doi: 10.1016/j.intimp.2016.09.019.




DOI: https://doi.org/10.24294/ti.v3.i2.96

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Naoya Mikita

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.